Travere Therapeutics Statistics Share Statistics Travere Therapeutics has 89.14M
shares outstanding. The number of shares has increased by 16.1%
in one year.
Shares Outstanding 89.14M Shares Change (YoY) 16.1% Shares Change (QoQ) 0.07% Owned by Institutions (%) 99.99% Shares Floating 86.77M Failed to Deliver (FTD) Shares 147 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 12.11M, so 13.58% of the outstanding
shares have been sold short.
Short Interest 12.11M Short % of Shares Out 13.58% Short % of Float 13.68% Short Ratio (days to cover) 7.07
Valuation Ratios The PE ratio is -4.27 and the forward
PE ratio is 41.47.
Travere Therapeutics's PEG ratio is
-0.02.
PE Ratio -4.27 Forward PE 41.47 PS Ratio 5.89 Forward PS 3.3 PB Ratio 23.26 P/FCF Ratio -4.06 PEG Ratio -0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Travere Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.08,
with a Debt / Equity ratio of 6.8.
Current Ratio 2.08 Quick Ratio 2.04 Debt / Equity 6.8 Debt / EBITDA -1.51 Debt / FCF -1.19 Interest Coverage -28.67
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $605.65K Profits Per Employee $-835.18K Employee Count 385 Asset Turnover 0.39 Inventory Turnover 1.25
Taxes Income Tax 120K Effective Tax Rate -0.04%
Stock Price Statistics The stock price has increased by 97.09% in the
last 52 weeks. The beta is 0.79, so Travere Therapeutics's
price volatility has been higher than the market average.
Beta 0.79 52-Week Price Change 97.09% 50-Day Moving Average 16.78 200-Day Moving Average 18 Relative Strength Index (RSI) 78.22 Average Volume (20 Days) 1,586,540
Income Statement In the last 12 months, Travere Therapeutics had revenue of 233.18M
and earned -321.55M
in profits. Earnings per share was -4.08.
Revenue 233.18M Gross Profit 225.43M Operating Income -320.63M Net Income -321.55M EBITDA -265.77M EBIT -309.33M Earnings Per Share (EPS) -4.08
Full Income Statement Balance Sheet The company has 58.53M in cash and 401.58M in
debt, giving a net cash position of -343.05M.
Cash & Cash Equivalents 58.53M Total Debt 401.58M Net Cash -343.05M Retained Earnings -1.45B Total Assets 555.31M Working Capital 190.03M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -237.47M
and capital expenditures -101.21M, giving a free cash flow of -338.69M.
Operating Cash Flow -237.47M Capital Expenditures -101.21M Free Cash Flow -338.69M FCF Per Share -4.29
Full Cash Flow Statement Margins Gross margin is 96.68%, with operating and profit margins of -137.51% and -137.9%.
Gross Margin 96.68% Operating Margin -137.51% Pretax Margin -137.45% Profit Margin -137.9% EBITDA Margin -113.98% EBIT Margin -137.51% FCF Margin -145.25%
Dividends & Yields TVTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for TVTX is $32,
which is 47.9% higher than the current price. The consensus rating is "Buy".
Price Target $32 Price Target Difference 47.9% Analyst Consensus Buy Analyst Count 15
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 2, 2012. It was a
backward
split with a ratio of 1:9.
Last Split Date Nov 2, 2012 Split Type backward Split Ratio 1:9
Scores Altman Z-Score -1.99 Piotroski F-Score 4
